Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Endo files Chapter 11 bankruptcy, enters agreement with debt holders » 09:30
08/17/22
08/17
09:30
08/17/22
09:30
ENDP

Endo

/

+

Endo International…

Endo International announced that it has entered into a restructuring support agreement with holders of more than a majority of Endo's first lien debt on a sale transaction that would reduce "outstanding indebtedness, address remaining opioid and other litigation-related claims, and best position Endo for the future." Under the RSA, the debtholder group has committed to providing total purchase consideration of approximately $6B in the form of a credit bid, plus assumption of certain liabilities, for substantially all of the company's assets. The transaction contemplates that the purchaser will: Offer employment to all of Endo's active team members; Establish voluntary trusts, to be funded with $550M over 10 years, whereby future proceeds will be set aside for certain opioid claims; and have net funded leverage in an amount no greater than 4.5 times. This "stalking horse" bid will be subject to higher or otherwise better offers, the company said in a statement. To facilitate the sale process and provide an appropriate forum for bringing closure to opioid-related and other uncertainties, Endo and certain of its subsidiaries initiated voluntary prearranged Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Endo's India-based entities are not part of the Chapter 11 proceedings. The company expects to file recognition proceedings in Canada, the United Kingdom, and Australia. Shares of Endo are up 15% to 43c in premarket trading.

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Monday
Hot Stocks
Paulson buys VMware, exits DiDi in Q2 » 17:16
08/15/22
08/15
17:16
08/15/22
17:16
VMW

VMware

$122.42 /

+0.46 (+0.38%)

, IS

ironSource

$4.45 /

+0.43 (+10.70%)

, GLD

SPDR Gold Shares

$165.73 /

-2.14 (-1.27%)

, DIDIY

Didi Global

$2.31 /

+ (+0.00%)

, XOM

Exxon Mobil

$92.32 /

-1.68 (-1.79%)

, OIH

Oil Services Holders Trust

$233.06 /

-9.82 (-4.04%)

, TIMB

Tim SA

$12.24 /

-0.305 (-2.43%)

, HZNP

Horizon Therapeutics

$64.90 /

-2.58 (-3.82%)

, BHC

Bausch Health

$6.28 /

+0.265 (+4.41%)

, ENDP

Endo

/

+

, OXY

Occidental Petroleum

$64.34 /

-1.37 (-2.08%)

, PCRX

Pacira

$57.77 /

+0.4 (+0.70%)

, NMRK

Newmark

$11.25 /

+0.17 (+1.53%)

, BSIG

BrightSphere

$20.13 /

+0.055 (+0.27%)

, KWEB

KraneShares CSI China Internet ETF

$28.84 /

+0.21 (+0.73%)

John Paulson's…

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of June 30, 2022. The fund's five new buys during the second quarter included, by size of position, VMware (VMW) and IronSource (IS). Paulson exited six positions during the quarter, including by size of previous position SPDR Gold Shares (GLD), DiDi (DIDIY), Exxon Mobil (XOM), VanEck Oil Services ETF (OIH), and TIM SA (TIMB). The fund increased its stake in two holdings, namely Horizon Therapeutics (HZNP) and Bausch Health (BHC). Paulson reduced its stake in four holdings, including by size of previous position Endo (ENDP), Occidental (OXY), Pacira Biosciences (PCRX) and Newmark (NMRK). The fund's top holdings as of June 30, in order of size, were Horizon Therapeutics, Bausch Health, BrightSphere (BSIG), Occidental, and KraneShares CSI China Internet ETF (KWEB).

ShowHide Related Items >><<
XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

VMW VMware
$122.42 /

+0.46 (+0.38%)

TIMB Tim SA
$12.24 /

-0.305 (-2.43%)

PCRX Pacira
$57.77 /

+0.4 (+0.70%)

OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

NMRK Newmark
$11.25 /

+0.17 (+1.53%)

IS ironSource
$4.45 /

+0.43 (+10.70%)

HZNP Horizon Therapeutics
$64.90 /

-2.58 (-3.82%)

GLD SPDR Gold Shares
$165.73 /

-2.14 (-1.27%)

ENDP Endo
/

+

DIDIY Didi Global
$2.31 /

+ (+0.00%)

BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

VMW VMware
$122.42 /

+0.46 (+0.38%)

07/06/22 Raymond James
VMware downgraded to Market Perform from Outperform at Raymond James
05/31/22 Deutsche Bank
VMware price target raised to $142.50 from $135 at Deutsche Bank
05/27/22 RBC Capital
VMware downgraded to Sector Perform from Outperform at RBC Capital
05/27/22 Mizuho
Broadcom price target raised to $725 from $700 at Mizuho
IS ironSource
$4.45 /

+0.43 (+10.70%)

08/11/22 Credit Suisse
ironSource downgraded to Neutral from Outperform at Credit Suisse
08/10/22 Citi
AppLovin bid for Unity faces 'several challenges,' says Citi
08/10/22 Barclays
Unity price target raised to $49 from $35 at Barclays
08/09/22 Stifel
Unity price target raised to $60 at Stifel after AppLovin proposal
GLD SPDR Gold Shares
$165.73 /

-2.14 (-1.27%)

DIDIY Didi Global
$2.31 /

+ (+0.00%)

XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

08/10/22 Credit Suisse
Exxon Mobil assumed with an Outperform at Credit Suisse
08/01/22 BofA
Exxon Mobil price target raised to $123 from $120 at BofA
07/28/22 Stifel
NextDecade upgraded to Hold from Sell at Stifel
07/20/22 HSBC
Exxon Mobil price target raised to $97.50 from $92.50 at HSBC
OIH Oil Services Holders Trust
$233.06 /

-9.82 (-4.04%)

TIMB Tim SA
$12.24 /

-0.305 (-2.43%)

06/30/22 Barclays
Tim SA price target raised to $17 from $16 at Barclays
04/18/22 Citi
Tim SA initiated with a Buy at Citi
02/01/22 Barclays
Tim SA price target lowered to $16 from $17 at Barclays
11/10/21 UBS
Tim SA upgraded to Buy from Neutral at UBS
HZNP Horizon Therapeutics
$64.90 /

-2.58 (-3.82%)

08/04/22 BMO Capital
Horizon Therapeutics price target lowered to $117 from $145 at BMO Capital
08/04/22 UBS
Horizon Therapeutics downgraded to Neutral from Buy at UBS
08/04/22 SVB Securities
Horizon Therapeutics downgraded to Market Perform from Outperform at SVB Securities
08/03/22 Stifel
Horizon Therapeutics price target lowered to $138 from $140 at Stifel
BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

07/29/22 RBC Capital
Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
07/29/22 RBC Capital
Bausch Health downgraded to Sector Perform from Outperform at RBC Capital
07/28/22 Truist
Bausch Health downgraded to Hold from Buy at Truist
07/28/22 Stifel
Stifel puts Bausch rating under review amid 'significant confusion'
ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

07/28/22 MKM Partners
Climate bill contains 'strong benefit' to carbon capture E&Ps, says MKM
07/26/22 Barclays
Occidental Petroleum price target lowered to $79 from $84 at Barclays
07/20/22 MKM Partners
Occidental Petroleum assumed with a Neutral at MKM Partners
07/19/22 Truist
Occidental Petroleum price target raised to $105 from $93 at Truist
PCRX Pacira
$57.77 /

+0.4 (+0.70%)

07/21/22 Piper Sandler
Pacira price target lowered to $80 from $84 at Piper Sandler
03/01/22 Northland
Pacira price target raised to $67 from $61 at Northland
02/25/22 H.C. Wainwright
Pacira price target raised to $90 from $86 at H.C. Wainwright
01/19/22 Barclays
Pacira price target raised to $96 from $92 at Barclays
NMRK Newmark
$11.25 /

+0.17 (+1.53%)

04/18/22 Piper Sandler
Newmark downgraded to Neutral from Overweight at Piper Sandler
04/05/22 Goldman Sachs
Newmark initiated with a Neutral at Goldman Sachs
03/10/22 Wolfe Research
Newmark downgraded to Peer Perform from Outperform at Wolfe Research
03/10/22 Wolfe Research
Newmark downgraded to Peer Perform from Outperform at Wolfe Research
BSIG BrightSphere
$20.13 /

+0.055 (+0.27%)

04/08/22 Morgan Stanley
BrightSphere price target lowered to $27 from $29 at Morgan Stanley
12/14/21 Morgan Stanley
BrightSphere downgraded at Morgan Stanley on more balanced risk/reward
12/14/21 Morgan Stanley
BrightSphere downgraded to Equal Weight from Overweight at Morgan Stanley
10/29/21 Keefe Bruyette
BrightSphere downgraded to Market Perform from Outperform at Keefe Bruyette
KWEB KraneShares CSI China Internet ETF
$28.84 /

+0.21 (+0.73%)

03/16/22 US Tiger
China Internet sector upgraded to Outperform from Neutral at US Tiger
XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

VMW VMware
$122.42 /

+0.46 (+0.38%)

PCRX Pacira
$57.77 /

+0.4 (+0.70%)

OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

NMRK Newmark
$11.25 /

+0.17 (+1.53%)

IS ironSource
$4.45 /

+0.43 (+10.70%)

HZNP Horizon Therapeutics
$64.90 /

-2.58 (-3.82%)

ENDP Endo
/

+

BSIG BrightSphere
$20.13 /

+0.055 (+0.27%)

BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

VMW VMware
$122.42 /

+0.46 (+0.38%)

OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

ENDP Endo
/

+

DIDIY Didi Global
$2.31 /

+ (+0.00%)

BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

VMW VMware
$122.42 /

+0.46 (+0.38%)

PCRX Pacira
$57.77 /

+0.4 (+0.70%)

OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

IS ironSource
$4.45 /

+0.43 (+10.70%)

HZNP Horizon Therapeutics
$64.90 /

-2.58 (-3.82%)

ENDP Endo
/

+

BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

XOM Exxon Mobil
$92.32 /

-1.68 (-1.79%)

OXY Occidental Petroleum
$64.34 /

-1.37 (-2.08%)

OIH Oil Services Holders Trust
$233.06 /

-9.82 (-4.04%)

KWEB KraneShares CSI China Internet ETF
$28.84 /

+0.21 (+0.73%)

ENDP Endo
/

+

DIDIY Didi Global
$2.31 /

+ (+0.00%)

BHC Bausch Health
$6.28 /

+0.265 (+4.41%)

GLD SPDR Gold Shares
$165.73 /

-2.14 (-1.27%)

Friday
Options
Largest borrow rate increases among liquid names » 08:45
08/12/22
08/12
08:45
08/12/22
08:45
WRBY

Warby Parker

$16.89 /

+2.765 (+19.58%)

, EXPI

eXp World Holdings

$17.75 /

-0.035 (-0.20%)

, NEGG

Newegg Commerce

$3.85 /

+ (+0.00%)

, VTNR

Vertex Energy

$7.04 /

-0.875 (-11.05%)

, SAVA

Cassava Sciences

$19.85 /

+0.03 (+0.15%)

, BCAB

BioAtla

$7.95 /

+1.26 (+18.83%)

, AVDL

Avadel Pharmaceuticals

$6.85 /

-0.27 (-3.79%)

, DWAC

Digital World Acquisition

$30.34 /

+0.07 (+0.23%)

, ENDP

Endo

/

+

, CAN

Canaan

$4.08 /

+ (+0.00%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Warby Parker (WRBY) 13.35% +2.28, eXp World Holdings (EXPI) 4.08% +0.90, Newegg Commerce (NEGG) 68.02% +0.75, Vertex Energy (VTNR) 5.67% +0.69, Cassava Sciences (SAVA) 42.09% +0.54, BioAtla (BCAB) 1.40% +0.29, Avadel Pharmaceuticals (AVDL) 12.01% +0.28, Digital World Acquisition Corp (DWAC) 50.81% +0.25, Endo (ENDP) 6.77% +0.20, and Canaan Inc (CAN) 1.22% +0.18.

ShowHide Related Items >><<
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

07/22/22 Piper Sandler
Warby Parker initiated with an Overweight at Piper Sandler
07/21/22 Goldman Sachs
Warby Parker price target lowered to $12 from $16 at Goldman Sachs
07/20/22 Stifel
Warby Parker price target lowered to $11 from $15 at Stifel
06/27/22 Loop Capital
Warby Parker price target lowered to $15 from $18 at Loop Capital
EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

08/04/22 DA Davidson
eXp World Holdings price target lowered to $22 from $28 at DA Davidson
05/05/22 DA Davidson
eXp World Holdings price target lowered to $34 from $45 at DA Davidson
NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

08/10/22 Oppenheimer
Vertex Energy downgraded to Perform from Outperform at Oppenheimer
08/10/22 H.C. Wainwright
Vertex Energy price target lowered to $15 from $25 at H.C. Wainwright
07/07/22 Oppenheimer
Vertex Energy initiated with an Outperform at Oppenheimer
06/08/22 Stifel
Vertex Energy price target raised to $20 from $14 at Stifel
SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

08/11/22 B. Riley
Cassava Sciences price target lowered to $44 from $58 at B. Riley
06/02/22 Univest Securities
Univest keeps Sell on Cassava after medical journal retracts article
05/06/22 Univest Securities
Univest says Cassava enrollment still 'severely lags' others in Alzheimer's
05/06/22 B. Riley
Cassava Sciences price target lowered to $58 from $72 at B. Riley
BCAB BioAtla
$7.95 /

+1.26 (+18.83%)

08/10/22 H.C. Wainwright
BioAtla price target lowered to $20 from $25 at H.C. Wainwright
05/05/22 Credit Suisse
BioAtla downgraded to Neutral from Outperform at Credit Suisse
03/21/22 H.C. Wainwright
BioAtla initiated with a Buy at H.C. Wainwright
10/14/21 BTIG
BioAtla assumed with a Buy at BTIG
AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
CAN Canaan
$4.08 /

+ (+0.00%)

07/06/22 H.C. Wainwright
Canaan initiated with a Buy at H.C. Wainwright
06/07/22 Benchmark
Benchmark starts Canaan with Buy as 'indirect' bitcoin growth play
06/07/22 Benchmark
Canaan initiated with a Buy at Benchmark
05/16/22 DA Davidson
Canaan price target lowered to $10 from $15 at DA Davidson
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

BCAB BioAtla
$7.95 /

+1.26 (+18.83%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

  • 29
    Sep
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
08/11/22
08/11
08:45
08/11/22
08:45
ISPO

Inspirato

$3.91 /

-1.085 (-21.74%)

, MVST

Microvast

$2.83 /

+0.19 (+7.20%)

, FFIE

Faraday Future

$2.58 /

+0.09 (+3.61%)

, TIGR

UP Fintech

$3.71 /

+0.205 (+5.86%)

, HYLN

Hyliion Holdings

$4.61 /

+0.2 (+4.54%)

, EVGO

EVgo

$10.60 /

+1.33 (+14.35%)

, ENDP

Endo

/

+

, YELL

Yellow Corp

$7.90 /

+0.71 (+9.87%)

, AMRS

Amyris

$3.25 /

+0.965 (+42.23%)

, CVNA

Carvana

$47.24 /

+5.82 (+14.05%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Inspirato (ISPO) 67.87% +16.69, Microvast Holdings (MVST) 12.79% +6.37, Faraday Future Intelligent Electric (FFIE) 6.66% +0.82, UP Fintech Holding Ltd (TIGR) 34.99% +0.64, Hyliion Holdings (HYLN) 1.93% +0.43, EVgo (EVGO) 42.02% +0.40, Endo (ENDP) 7.60% +0.33, Yellow Corp (YELL) 3.48% +0.29, Amyris (AMRS) 2.44% +0.28, and Carvana (CVNA) 1.29% +0.25.

ShowHide Related Items >><<
YELL Yellow Corp
$7.90 /

+0.71 (+9.87%)

MVST Microvast
$2.83 /

+0.19 (+7.20%)

ISPO Inspirato
$3.91 /

-1.085 (-21.74%)

HYLN Hyliion Holdings
$4.61 /

+0.2 (+4.54%)

FFIE Faraday Future
$2.58 /

+0.09 (+3.61%)

EVGO EVgo
$10.60 /

+1.33 (+14.35%)

ENDP Endo
/

+

CVNA Carvana
$47.24 /

+5.82 (+14.05%)

AMRS Amyris
$3.25 /

+0.965 (+42.23%)

ISPO Inspirato
$3.91 /

-1.085 (-21.74%)

08/09/22 Cantor Fitzgerald
Inspirato upgraded to Overweight from Neutral at Cantor Fitzgerald
08/08/22 Piper Sandler
Inspirato price target lowered to $7 from $9 at Piper Sandler
07/22/22 Cantor Fitzgerald
Inspirato assumed with a Neutral at Cantor Fitzgerald
06/28/22 Stifel
Inspirato price target lowered to $6 from $7 at Stifel
MVST Microvast
$2.83 /

+0.19 (+7.20%)

04/01/22 Morgan Stanley
Microvast price target lowered to $4 from $6 at Morgan Stanley
12/17/21 Piper Sandler
Microvast initiated with a Neutral at Piper Sandler
FFIE Faraday Future
$2.58 /

+0.09 (+3.61%)

11/16/21 Wedbush
Wedbush downgrades Faraday Future to Neutral, sees shares in 'penalty box'
11/16/21 Wedbush
Faraday Future downgraded to Neutral from Outperform at Wedbush
10/25/21 Wedbush
Hertz mega deal another 'feather in the cap' for Tesla, says Wedbush
08/17/21 Wedbush
Wedbush bullish on Faraday Future, initiates with an Outperform
TIGR UP Fintech
$3.71 /

+0.205 (+5.86%)

06/13/22 Daiwa
UP Fintech price target raised to $5.70 from $5.40 at Daiwa
05/19/22 China Renaissance
UP Fintech assumed with Hold from Buy at China Renaissance
12/01/21 Citi
UP Fintech price target lowered to $7.58 from $18.22 at Citi
10/29/21 Alliance Global Partners
MICT could benefit on top China brokers' fallout, says Alliance Global Partners
HYLN Hyliion Holdings
$4.61 /

+0.2 (+4.54%)

08/11/22 Cantor Fitzgerald
Hyliion Holdings downgraded to Neutral from Overweight at Cantor Fitzgerald
08/11/22 Cantor Fitzgerald
Hyliion Holdings downgraded to Neutral from Overweight at Cantor Fitzgerald
06/21/22 JPMorgan
Hyliion downgraded to Underweight on rising competition at JPMorgan
06/21/22 JPMorgan
Hyliion Holdings downgraded to Underweight from Neutral at JPMorgan
EVGO EVgo
$10.60 /

+1.33 (+14.35%)

07/07/22 Jefferies
Jefferies starts EVgo at Hold, projects profitability by 2025
07/07/22 Jefferies
EVgo initiated with a Hold at Jefferies
06/08/22 Capital One
EVgo upgraded to Overweight from Equalweight at Capital One
05/16/22 Citi
EVgo price target lowered to $10 from $11 at Citi
ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
YELL Yellow Corp
$7.90 /

+0.71 (+9.87%)

01/04/22 Stephens
Yellow Corp price target raised to $15 from $12 at Stephens
11/09/21 Stifel
Yellow Corp price target raised to $13 from $7 at Stifel
AMRS Amyris
$3.25 /

+0.965 (+42.23%)

08/10/22 Roth Capital
Roth Capital downgrades Amyris to Neutral, lowers price target to $2
08/10/22 Roth Capital
Amyris downgraded to Neutral from Buy at Roth Capital
06/24/22 JPMorgan
Amyris initiated with a Neutral at JPMorgan
05/25/22 Piper Sandler
Amyris initiated with a Neutral at Piper Sandler
CVNA Carvana
$47.24 /

+5.82 (+14.05%)

08/08/22 Deutsche Bank
Carvana price target lowered to $42 from $54 at Deutsche Bank
08/08/22 DA Davidson
Carvana price target lowered to $42 from $49 at DA Davidson
08/08/22 JPMorgan
Carvana downgraded to Underweight from Neutral at JPMorgan
08/05/22 BofA
Carvana liquidity concerns easing as margins improve, says BofA
YELL Yellow Corp
$7.90 /

+0.71 (+9.87%)

MVST Microvast
$2.83 /

+0.19 (+7.20%)

ISPO Inspirato
$3.91 /

-1.085 (-21.74%)

HYLN Hyliion Holdings
$4.61 /

+0.2 (+4.54%)

FFIE Faraday Future
$2.58 /

+0.09 (+3.61%)

EVGO EVgo
$10.60 /

+1.33 (+14.35%)

ENDP Endo
/

+

CVNA Carvana
$47.24 /

+5.82 (+14.05%)

AMRS Amyris
$3.25 /

+0.965 (+42.23%)

  • 22
    Apr
EVGO EVgo
$10.60 /

+1.33 (+14.35%)

ENDP Endo
/

+

CVNA Carvana
$47.24 /

+5.82 (+14.05%)

YELL Yellow Corp
$7.90 /

+0.71 (+9.87%)

MVST Microvast
$2.83 /

+0.19 (+7.20%)

ISPO Inspirato
$3.91 /

-1.085 (-21.74%)

HYLN Hyliion Holdings
$4.61 /

+0.2 (+4.54%)

FFIE Faraday Future
$2.58 /

+0.09 (+3.61%)

EVGO EVgo
$10.60 /

+1.33 (+14.35%)

ENDP Endo
/

+

CVNA Carvana
$47.24 /

+5.82 (+14.05%)

AMRS Amyris
$3.25 /

+0.965 (+42.23%)

TIGR UP Fintech
$3.71 /

+0.205 (+5.86%)

MVST Microvast
$2.83 /

+0.19 (+7.20%)

ISPO Inspirato
$3.91 /

-1.085 (-21.74%)

FFIE Faraday Future
$2.58 /

+0.09 (+3.61%)

EVGO EVgo
$10.60 /

+1.33 (+14.35%)

ENDP Endo
/

+

CVNA Carvana
$47.24 /

+5.82 (+14.05%)

AMRS Amyris
$3.25 /

+0.965 (+42.23%)

Options
Endo options imply 43.5% move in share price post-earnings » 14:34
08/09/22
08/09
14:34
08/09/22
14:34
ENDP

Endo

/

+

Pre-earnings options…

Pre-earnings options volume in Endo is 2.4x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 43.5%, or 0c, after results are released. Median move over the past eight quarters is 13.5%.

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Hot Stocks
Endo expects pre-arranged filing under Chapter 11 'imminently' » 08:55
08/09/22
08/09
08:55
08/09/22
08:55
ENDP

Endo

/

+

As of June 30, 2022, the…

As of June 30, 2022, the company had approximately $1.2 billion in unrestricted cash; $8.1 billion of debt; and a net debt to adjusted EBITDA ratio of 5.6. These amounts reflect the company's payment of $35 million to acquire 6 sterile injectable product candidates and a $30 million upfront payment related to a Phase 3 injectable compound for the treatment of osteoarthritis knee pain. Second-quarter 2022 net cash used in operating activities was $133 million compared to $155 million provided by operating activities during the second-quarter 2021. This change was primarily attributable to decreased revenues. The company remains in constructive negotiations with an ad hoc group of first lien creditors, among other parties. In light of the progress to date, the company expects that these negotiations will likely result in a pre-arranged filing under Chapter 11 of the U.S. Bankruptcy Code by Endo International plc and substantially all of its subsidiaries, which could occur imminently.

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Earnings
Endo reports Q2 adjusted EPS (3c), consensus (14c) » 08:47
08/09/22
08/09
08:47
08/09/22
08:47
ENDP

Endo

/

+

Reports Q2 revenue…

Reports Q2 revenue $569.11M, consensus $529.94M. As of June 30, the Company had approximately $1.2B in unrestricted cash; $8.1B of debt; and a net debt to adjusted EBITDA ratio of 5.6. These amounts reflect the Company's payment of $35M to acquire 6 sterile injectable product candidates and a $30M upfront payment related to a Phase 3 injectable compound for the treatment of osteoarthritis knee pain.

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Options
Endo options imply 25.5% move in share price post-earnings » 15:11
08/08/22
08/08
15:11
08/08/22
15:11
ENDP

Endo

/

+

Pre-earnings options…

Pre-earnings options volume in Endo is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 25.5%, or 0c, after results are released. Median move over the past eight quarters is 13.5%.

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Hot Stocks
Buxton Helmsley sends letter to Endo directors relating to financial disclosures » 06:11
07/26/22
07/26
06:11
07/26/22
06:11
ENDP

Endo

/

+

The Buxton Helmsley…

The Buxton Helmsley Group, the New York City-based investment advisor to clients with financial interests in Endo International, issued an open letter to directors of the company and its financial auditor, PricewaterhouseCoopers LLP, relating to financial disclosures. Reference Link

ShowHide Related Items >><<
ENDP Endo
/

+

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Over a month ago
Hot Stocks
Tiziana Life Sciences names Matthew Davis, MD, RPh as Chief Medical Officer » 06:04
07/18/22
07/18
06:04
07/18/22
06:04
TLSA

Tiziana Life Sciences

/

+

, ENDP

Endo

/

+

Tiziana Life Sciences…

Tiziana Life Sciences (TLSA) announces that it has appointed Matthew Davis, MD, RPh as its Chief Medical Officer and Acting Chief Scientific Officer, effective immediately. Dr. Davis will report to Gabriele Cerrone, Executive Chairman and interim CEO of Tiziana. Dr. Davis previously served as Chief Scientific Officer and Chief Medical Officer at Endo Pharmaceuticals (ENDP) where he restructured the R&D department and collaborated to obtain BLA approval for QWO.

ShowHide Related Items >><<
TLSA Tiziana Life Sciences
/

+

ENDP Endo
/

+

TLSA Tiziana Life Sciences
/

+

06/13/22 ThinkEquity
Tiziana Life Sciences initiated with a Buy at ThinkEquity
01/24/22 B. Riley
Tiziana Life Sciences price target lowered to $3 from $8 at B. Riley
ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

ENDP Endo
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.